Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

Jill Stein
Published: Friday, Aug 31, 2012
Dr. Philip L. McCarthy

Philip L. McCarthy, MD

The immunomodulator lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma compared with placebo, according to the results of the phase III CALGB 100104 study.

McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication